Hemispherx Biopharma Inc

Hemispherx Biopharma to begin two clinical trials at two major US cancer centers

Hemispherx BioPharma Inc (NYSE American:HEB) CEO Tom Equels sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Equels says the company will begin clinical trials at the Roswell Park Comprehensive Cancer Center to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck's Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer.

A second clinical trial combining Ampligen with Keytruda in ovarian cancer is scheduled to launch later this month at the University of Pittsburgh.

Quick facts: Hemispherx Biopharma Inc

Price: $1.93

Market: NYSE
Market Cap: $4.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Hemispherx Biopharma Inc named herein, including the promotion by the Company of Hemispherx Biopharma Inc in any Content on the Site, the...



Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

3 days, 3 hours ago

2 min read